Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

In Trodelvy's favour is that the outlook for patients with HR+/HER2- breast cancer who have progressed despite earlier hormonal therapies, CDK4/6 inhibitors and multiple lines of chemo is pretty ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics Second Quarter 2025 Financial Results Call. Please be ...

(Reuters) -Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year ...